Immunocore is developing drugs known as "ImmTACs"
that exploit the power of the body's own immune system to find and
kill diseased cells.
AstraZeneca said on Wednesday its MedImmune unit would pay
Immunocore $20 million upfront per program and the biotech firm
would then be eligible to get up to $300 million in development and
commercial milestone payments for each target program, plus
royalties on any eventual sales.
(Reporting by Ben Hirschler)
[© 2014 Thomson Reuters. All rights
2014 Reuters. All rights reserved. This material may not be
published, broadcast, rewritten or redistributed.